<div id="readability-page-1"><p>TuHURA Biosciences (NASDAQ:HURA - Get Free Report) is projected to announce its resultson Friday, May 15th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter.</p><div><p><span></span><span>Get <strong>TuHURA Biosciences</strong> alerts:</span></p></div><p>TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01).  On average, analysts expect TuHURA Biosciences to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year. </p><h2>TuHURA Biosciences Trading Down 5.5%</h2><p>TuHURA Biosciences stock opened at $2.40 on Friday. The company has a market capitalization of $152.83 million, a price-to-earnings ratio of -3.81 and a beta of -0.01. TuHURA Biosciences has a 12 month low of $0.41 and a 12 month high of $4.20. The stock's 50 day moving average is $2.05 and its 200-day moving average is $1.60. </p><h2>Analysts Set New Price Targets</h2><p>A number of equities research analysts have recently weighed in on HURA shares. Weiss Ratings  reissued a &#34;sell (e+)&#34; rating on shares of TuHURA Biosciences in a report on Tuesday, April 21st. Citigroup started coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They issued an &#34;outperform&#34; rating on the stock. Citizens Jmp started coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They issued a &#34;market outperform&#34; rating and a $9.00 price objective for the company. HC Wainwright  reissued a &#34;buy&#34; rating and issued a $10.00 price objective on shares of TuHURA Biosciences in a report on Tuesday, February 3rd. Finally, Rodman &amp; Renshaw assumed coverage on shares of TuHURA Biosciences in a research report on Wednesday, April 15th. They issued a &#34;buy&#34; rating for the company. Five investment analysts have rated the stock with a Buy rating and one  has assigned  a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $9.00.</p><p><b>Check Out Our Latest Analysis on TuHURA Biosciences</b></p><h2>Hedge Funds Weigh In On TuHURA Biosciences</h2><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new stake in shares of  TuHURA Biosciences in the third quarter worth $26,000.  JPMorgan Chase &amp; Co. bought a new position in  TuHURA Biosciences during the 2nd quarter worth $27,000.  Invesco Ltd. bought a new position in  TuHURA Biosciences during the 2nd quarter worth approximately $30,000.  MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of  TuHURA Biosciences during the second quarter worth $31,000.  Finally, Bank of America Corp DE bought a new position in  TuHURA Biosciences during the fourth quarter worth $59,000. 0.62% of the stock is currently owned by institutional investors and hedge funds. </p><h2>TuHURA Biosciences Company Profile</h2> (Get Free Report)<p>TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company's core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.  </p><p>At the heart of TuHURA's approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than TuHURA Biosciences</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFVSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFVSQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in TuHURA Biosciences Right Now?</h2><p>Before you consider TuHURA Biosciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.</p><p>While TuHURA Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

HURA

LABU

SBIO

<p>TuHURA Biosciences (NASDAQ:HURA) is set to announce its earnings on Friday, May 15, with analysts expecting a loss of $0.12 per share. The company previously reported a loss of $0.13 per share, missing estimates. Currently, TuHURA's stock is trading at $2.40, down 5.5%, with a market cap of $152.83 million. Analysts have mixed ratings, with a consensus of "Moderate Buy" and an average target price of $9.00. Institutional investors have recently increased their stakes in the company, which focuses on developing novel therapeutics through proteomics.</p>

Market Beat

TuHURA Biosciences

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

iShares Biotechnology ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Citigroup

Citizens Financial

Virtu Finc

JPMorgan Chase

Invesco

Bank of America

CITIGROUP INC 6.250 NON CUM SER II PFD WI

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SR I

CITIZENS FINANCIAL GROUP INC 5% DEP SHS EA REP 1/40TH NON CUM SER E

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SER H

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

TuHURA Biosciences (HURA) Expected to Announce Earnings on Friday